Novera CJC-1295 – With DAC 10mg

CJC-1295 with DAC is a synthetic long-acting analog of growth hormone releasing hormone (GHRH) engineered to produce prolonged stimulation of growth hormone secretion in controlled experimental settings. Built on the first 29 amino acids of human GHRH with four strategic substitutions and a drug affinity complex (DAC) linker, this peptide has demonstrated the ability to increase growth hormone levels by 2-10 times and sustain elevated average IGF-I levels by 1.5 to 3-fold for over a week following a single administration in research models. When you buy CJC-1295 with DAC from a reputable chemical supplier, you gain access to one of the most extensively characterized growth hormone secretagogues available for laboratory investigation.

CJC-1295 DAC is supplied exclusively for research and laboratory use by licensed professionals. It has not been evaluated by the FDA for any medical indication in humans, and it is not intended for human consumption. All data referenced below derive from peer-reviewed Phase 1 clinical pharmacology studies and preclinical experimental models conducted under controlled experimental conditions.

General Information About CJC-1295 with DAC

CJC-1295 with DAC is a synthetic peptide analog of growth hormone-releasing hormone originally developed by ConjuChem Biotechnologies in the early 2000s as part of a program to create long-acting GHRH analogs via albumin bioconjugation. The peptide structure is based on the minimal active fragment of human GHRH-GRF(1-29)-with four amino acid substitutions that dramatically improve the peptide’s stability: D-Alanine at position 2 to resist dipeptidyl peptidase IV (DPP-IV) cleavage, Glutamine at position 8 to prevent asparagine deamidation, Alanine at position 15 to stabilize the α-helical secondary structure, and Leucine at position 27 to eliminate methionine oxidation risk. The resulting modified peptide has an approximate molecular formula of C₁₆₅H₂₆₉N₄₇O₄₆ and a molecular weight of approximately 3,647 Da.

The defining feature of this compound is the drug affinity complex-a maleimidopropionic acid moiety attached to the ε-amino group of a C-terminal lysine derivative at position 30. After subcutaneous administration, this lysine derivative enables the peptide to form a covalent thioether bond with the free cysteine residue (Cys-34) on circulating serum albumin. CJC-1295 DAC enhances pharmacokinetics by binding to plasma proteins, yielding a peptide-albumin conjugate of approximately 67 kDa that resists renal filtration and proteolytic degradation. This mechanism extends the plasma half-life to approximately 6-8 days in healthy adults-compared to mere minutes for native GH releasing hormone and roughly 30 minutes for CJC-1295 without DAC.

At the receptor level, CJC-1295 with DAC binds the GHRH receptor (GHRHR), a class II G protein coupled receptor expressed on somatotroph cells in the anterior pituitary. Receptor binding activates stimulatory G proteins, which drive adenylyl cyclase to increase cyclic adenosine monophosphate (cAMP) production. Elevated cAMP levels activate protein kinases-specifically protein kinase A (PKA)-which initiate a cascade of cellular signaling pathways including phosphorylating transcription regulators such as CREB, ultimately driving GH gene expression and GH release from the pituitary gland. The secreted growth hormone then acts on liver cells via hepatic GH receptors, engaging the Janus kinase signal transducer and activator of transcription (JAK2-STAT5) pathway to stimulate IGF-I gene transcription and systemic insulin like growth factor production.

CJC-1295 with DAC Use in the Research Setting

CJC-1295 with DAC is supplied as a lyophilized powder intended for reconstitution and use in in vitro research settings only, within appropriately designed experimental models supervised by licensed professionals.

#1. Growth Hormone Stimulation Research

The landmark Phase 1 study by Teichman et al. (2006) demonstrated that single ascending subcutaneous doses of CJC-1295 DAC in healthy adults aged 21-61 produced dose-dependent increases in growth hormone levels, with CJC-1295 DAC capable of increasing growth hormone levels by 2-10 times over baseline. Growth hormone levels peak approximately 2 hours after CJC-1295 DAC administration, but critically, elevated GH persisted for over six days post-administration-a feature that distinguishes this long acting analog from virtually all other growth hormone releasing peptide compounds.

The mechanism underlying this sustained GH release centers on continuous stimulation of somatotroph cells in the anterior pituitary via the GHRHR-Gs-cAMP-PKA axis. This peptide appears to maintain its receptor interaction over days due to albumin conjugation protecting the active peptide from metabolic clearance. Data suggests that CJC-1295 DAC maintains physiological growth hormone release patterns: the Ionescu & Frohman (2006) study demonstrated that pulsatile secretion of GH persists during continuous stimulation, with pulse amplitude and frequency remaining unchanged-while basal (trough) GH levels increased approximately 7.5-fold, meaning CJC-1295 DAC may increase growth hormone levels by 7.5 times at the trough level.

Compared to natural GHRH (or sermorelin), which produces brief pulses lasting minutes, and CJC-1295 without DAC (modified GRF 1-29), which has a half-life of only 30 minutes and requires once daily administration or more frequent dosing to sustain GH elevation, CJC-1295 with DAC requires infrequent dosing-typically weekly or biweekly in published protocols. CJC-1295 is frequently combined with Ipamorelin in research protocols to maximize growth hormone release, as Ipamorelin acts through distinct ghrelin receptors on somatotrophs to provide synergistic GH stimulation through complementary molecular interactions.

“GH secretion was increased after CJC-1295 administration with preserved pulsatility. Basal (trough) GH levels were markedly increased (7.5-fold), and mean GH levels increased 46%.” – Ionescu & Frohman, The Journal of Clinical Endocrinology & Metabolism, 2006.

#2. IGF-1 Elevation Studies

Beyond direct GH stimulation, CJC-1295 DAC can elevate IGF-1 levels by 1.5 to 3-fold over baseline following a single subcutaneous dose, with this elevation sustained for approximately 9-11 days. In multiple-dose protocols (weekly or biweekly administration), average IGF-I levels remained above baseline for up to 28 days, providing researchers with a prolonged window of elevated insulin like growth factor signaling for investigation.

The downstream mechanism proceeds through well-characterized cellular functions: circulating GH binds hepatic GH receptors, triggering activation of the Janus kinase signal transducer pathway (JAK2 phosphorylation → STAT5 activation), which translocates to the nucleus and binds specific DNA sequences in the IGF-I gene promoter region, upregulating IGF-I gene expression and secretion into the bloodstream. This cascade of response elements ultimately drives the systemic anabolic effects observed in experimental models, including influences on protein synthesis, lean mass regulation, and bone structure remodeling.

#3. Body Composition Research Applications

CJC-1295 with DAC has been studied for its effects on muscle growth and recovery in preclinical research models. CJC-1295 with DAC may improve body composition by reducing fat and increasing muscle mass, though many claims regarding CJC-1295 with DAC’s benefits in fat loss or muscle building lack high-quality clinical support-published Phase 1 human trials focused primarily on pharmacokinetic and hormonal endpoints rather than long-term body composition outcomes.

In animal experimental models, albumin-conjugated GHRH analogs have demonstrated improved growth parameters including lean mass accrual, reduced subcutaneous fat mass, and enhanced muscle and bone structure compared to non-conjugated GHRH variants. These effects are mechanistically consistent with prolonged GH/IGF-1 exposure driving protein synthesis in skeletal muscle, lipolysis in fat tissue levels, and osteoblast activation improving bone density. Research using the GHRH knockout mouse model has further established that chronic GHRH signaling deficiency reduces total pituitary RNA encoding GH and GH mRNA levels, while restoration of GHRH signaling normalizes growth trajectories-supporting the mechanistic rationale for investigating CJC-1295 DAC’s body composition effects. The peptide is often discussed in bodybuilding and longevity communities, though researchers should note that human body composition data remains preliminary.

#4. Metabolic Function Research

Published human studies on CJC-1295 DAC’s metabolic effects remain limited. In the Phase 1 trials, metabolic endpoints such as blood sugar regulation, insulin sensitivity, and lipid profiles were not primary outcomes. Safety assessments included fasting glucose monitoring, showing no serious metabolic derangements in healthy adult populations over 4-7 week durations under controlled experimental conditions.

Mechanistically, the metabolic implications of sustained GH elevation are complex. Elevated growth hormone can antagonize insulin action at the androgen receptor and peripheral tissues, potentially affecting glucose metabolism, while insulin like growth factor exerts insulin-like effects on liver cells and skeletal muscle. The net metabolic impact depends on dose, duration, and baseline metabolic status. Continuous growth hormone elevation from CJC-1295 with DAC may lead to receptor desensitization over time with repeated exposure, though this remains a theoretical concern requiring further investigation in long-term research models. Research into myocardial function, neuronal function, and sperm production pathways influenced by the GH/IGF-1 axis represents emerging areas where CJC-1295 DAC may provide experimental utility.

“Data suggests that the sustained baseline GH elevation-rather than altered pulse characteristics-may be the primary mediator of metabolic effects observed with CJC-1295 DAC, making this compound uniquely informative for studies dissecting continuous versus pulsatile GH signaling.”

#5. Safety and Tolerability Research

In Phase 1 clinical studies, subcutaneous administration of CJC-1295 DAC in healthy adults was relatively well tolerated. No serious adverse events were reported across tested dose ranges. Common side effects of CJC-1295 with DAC may include injection site reactions and water retention, consistent with expected GH-mediated fluid shifts. The body’s endogenous feedback mechanisms-including somatostatin regulation and GH/IGF-1 negative feedback-appeared to remain intact, as evidenced by preserved pulsatile secretion patterns.

However, important caveats apply. CJC-1295 with DAC eliminates the natural pulsatile growth hormone release pattern at the baseline level (while preserving pulse superimposition), and the long-term consequences of sustained trough GH elevation on receptor’s structure and function-including potential receptor desensitization-remain inadequately characterized. No long-term clinical safety data exists. CJC-1295 DAC has not been evaluated by the FDA, and all available tolerability data derive from short-duration Phase 1 protocols examining peak growth hormone levels and pharmacokinetics rather than chronic safety endpoints.

<em>Important to Know:</em>

Buy CJC-1295 with DAC Online at FillerSupplies.com

When you buy CJC-1295 DAC for your research program, sourcing from an established chemical compounding facility with verifiable quality controls is essential. FillerSupplies.com has served the research community as a trusted supplier for over a decade, offering CJC-1295 with DAC and related compounds to licensed professionals worldwide. Whether you need to buy CJC-1295 DAC for GH stimulation studies, IGF-1 pathway research, or body composition investigations, FillerSupplies.com provides the reliability and service infrastructure that serious research demands. Researchers looking to cjc 1295 dac buy can also explore related compounds such as CJC-1295 without DAC for comparative pulsatile secretion studies.

• Authentic, certified products – original, quality-controlled compounds, warehouses worldwide.

• 11 years of reliability & trust – established supplier on the market since 2006.

• Temperature-controlled shipping – thermal packaging with ice gel / cold packs preserves peptide’s stability.

• Express worldwide shipping – next-day dispatch, global delivery.

• Best wholesale prices – tiered bulk discounts and price-match guarantee.

• Privacy guaranteed; expert support at (888) 392-6640, WhatsApp and email, Mon–Fri 10am–6pm EST.

• Supplied for research use only, to licensed professionals.

All CJC-1295 with DAC products are supplied strictly for research and laboratory use. They are not intended for human consumption, and buyers must hold appropriate credentials for research purposes.